Search hospitals > California > Whittier
Presbyterian Intercommunity Hospital
Claim this profileWhittier, California 90602
Global Leader in Cancer
Global Leader in Lung Cancer
Conducts research for Breast Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Recurrence
60 reported clinical trials
4 medical researchers
Summary
Presbyterian Intercommunity Hospital is a medical facility located in Whittier, California. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Recurrence and other specialties. Presbyterian Intercommunity Hospital is involved with conducting 60 clinical trials across 113 conditions. There are 4 research doctors associated with this hospital, such as Lisa S. Wang, Lisa Shing-E Lu Wang, M.D., Edwin Y. Lin, and Christopher R. Foss.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Lung Cancer
Global LeaderStage IV
Stage II
Stage III
Top PIs
Lisa S. WangPresbyterian Intercommunity Hospital2 years of reported clinical research
Studies Cancer
Studies Non-Small Cell Lung Cancer
22 reported clinical trials
51 drugs studied
Lisa Shing-E Lu Wang, M.D.PIH Health2 years of reported clinical research
Studies Breast Cancer
Studies Tumors
3 reported clinical trials
7 drugs studied
Edwin Y. LinPresbyterian Intercommunity Hospital5 years of reported clinical research
Studies Esophageal Adenocarcinoma
Studies Adenocarcinoma
3 reported clinical trials
11 drugs studied
Christopher R. FossPresbyterian Intercommunity Hospital1 year of reported clinical research
Studies Solid Tumors
Studies Tumors
2 reported clinical trials
22 drugs studied
Clinical Trials running at Presbyterian Intercommunity Hospital
Non-Small Cell Lung Cancer
Lung Cancer
Breast Cancer
Cancer
Colorectal Cancer
Bile Duct Cancer
Recurrence
Intrahepatic Cholangiocarcinoma
Endometrial Cancer
Gallbladder Cancer
Sotorasib
for Non-Small Cell Lung Cancer
This phase II Lung-MAP treatment trial studies the effect of AMG 510 in treating non-squamous non-small cell lung cancer that is stage IV or has come back (recurrent) and has a specific mutation in the KRAS gene, known as KRAS G12C. Mutations in this gene may cause the cancer to grow. AMG 510, a targeted treatment against the KRAS G12C mutation, may help stop the growth of tumor cells.
Recruiting2 awards Phase 219 criteria
Ramucirumab + Pembrolizumab vs Chemotherapy
for Non-Small Cell Lung Cancer
This phase III trial compares the effect of the combination of ramucirumab and pembrolizumab versus standard of care chemotherapy for the treatment of non-small cell lung cancer that is stage IV or that has come back after a period of improvement (recurrent). Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial may help doctors find out if giving ramucirumab with pembrolizumab is more effective at treating patients with stage IV or recurrent non-small cell lung cancer than standard chemotherapy.
Recruiting2 awards Phase 310 criteria
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Presbyterian Intercommunity Hospital?
Presbyterian Intercommunity Hospital is a medical facility located in Whittier, California. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Recurrence and other specialties. Presbyterian Intercommunity Hospital is involved with conducting 60 clinical trials across 113 conditions. There are 4 research doctors associated with this hospital, such as Lisa S. Wang, Lisa Shing-E Lu Wang, M.D., Edwin Y. Lin, and Christopher R. Foss.